Emodin-Conjugated PEGylation of Fe₃O₄ Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Kulkarni NM, Mannelli L, Zins M, et al. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology’s disease-focused panel for pancreatic ductal adenocarcinoma: part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals. Abdom Radiol. 2020;45(3):729–742. doi:10.1007/s00261-019-02290-y
   PubMedGoogle Scholar
• Kulkarni NM, Soloff EV, Tolat PP, et al. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology’s disease-focused panel for pancreatic ductal adenocarcinoma: part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdom Radiol. 2020;45(3):716–728. doi:10.1007/s00261-019-02289-5
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Huang X, Fan C, Zhu H, et al. Glypican-1-antibody-conjugated Gd – Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer. Int J Nanomedicine. 2018;13:2585–2599. doi:10.2147/IJN.S158559
   PubMed Web of Science ®Google Scholar
• Qiu W, Chen R, Chen X, et al. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer. Int J Nanomedicine. 2018;13:6809–6827. doi:10.2147/IJN.S177993
   PubMed Web of Science ®Google Scholar
• Akhter MH, Kumar S, Nomani S. Sonication tailored enhance cytotoxicity of naringenin nanoparticle in pancreatic cancer: design, optimization, and in vitro studies. Drug Dev Ind Pharm. 2020;46(4):659–672. doi:10.1080/03639045.2020.1747485
   PubMed Web of Science ®Google Scholar
• Tummers WS, Willmann JK, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg RJ. Advances in diagnostic and intraoperative molecular imaging of pancreatic cancer. Pancreas. 2018;47(6):675–689. doi:10.1097/MPA.0000000000001075
   PubMedGoogle Scholar
• Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156(7):2024–2040. doi:10.1053/j.gastro.2019.01.259
   PubMed Web of Science ®Google Scholar
• Israel LL. A nanomedicine approach to manage cancer – imaging pancreatic cancer using targeted iron oxide nanoparticles. EBioMedicine. 2018;30:7–8. doi:10.1016/j.ebiom.2018.03.011
   PubMedGoogle Scholar
• Lin L, Fan Y, Gao F, et al. UTMD-promoted co-delivery of gemcitabine and miR-21 inhibitor by dendrimer-entrapped gold nanoparticles for pancreatic cancer therapy. Theranostics. 2018;8(7):1923–1939. doi:10.7150/thno.22834
   PubMed Web of Science ®Google Scholar
• Ma X, Wang S, Hu L, et al. Imaging characteristics of USPIO nanoparticles (<5 nm) as MR contrast agent in vitro and in the liver of rats. Contrast Media Mol Imaging. 2019;2019:3687537. doi:10.1155/2019/3687537
   PubMedGoogle Scholar
• Chen X, Zhou H, Li X, et al. Plectin-1 targeted dual-modality nanoparticles for pancreatic cancer imaging. EBioMedicine. 2018;30:129–137. doi:10.1016/j.ebiom.2018.03.008
   PubMed Web of Science ®Google Scholar
• Khan S, Setua S, Kumari S, et al. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials. 2019;208:83–97. doi:10.1016/j.biomaterials.2019.04.005
   PubMed Web of Science ®Google Scholar
• Xie W, Guo Z, Gao F, et al. Shape-, size-and structure-controlled synthesis and biocompatibility of iron oxide nanoparticles for magnetic theranostics. Theranostics. 2018;8(12):3284–3307. doi:10.7150/thno.25220
   PubMed Web of Science ®Google Scholar
• Song L, Zang F, Song M, Chen G, Zhang Y, Gu N. Effective PEGylation of Fe3O4 nanomicelles for in vivo MR imaging. J Nanosci Nanotechnol. 2015;15(6):4111–4118. doi:10.1166/jnn.2015.9803
   PubMedGoogle Scholar
• Patsula V, Horák D, Kučka J, et al. Synthesis and modification of uniform PEG-neridronate-modified magnetic nanoparticles determines prolonged blood circulation and biodistribution in a mouse preclinical model. Sci Rep. 2019;9(1):10765. doi:10.1038/s41598-019-47262-w
   PubMed Web of Science ®Google Scholar
• Qie Y, Yuan H, Von Roemeling CA, et al. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci Rep. 2016;6(1):26269. doi:10.1038/srep26269
   PubMedGoogle Scholar
• Ahmad J, Ahmad MZ, Akhter H. Surface-engineered cancer nanomedicine: rational design and recent progress. Curr Pharm Des. 2020;26(11):1181–1190. doi:10.2174/1381612826666200214110645
   PubMed Web of Science ®Google Scholar
• Akhter MH, Beg S, Tarique M, et al. Receptor-based targeting of engineered nanocarrier against solid tumors: recent progress and challenges ahead. Biochim Biophys Acta Gen Subj. 2021;1865(2):129777. doi:10.1016/j.bbagen.2020.129777
   PubMed Web of Science ®Google Scholar
• Habban akhter M, Sateesh Madhav N, Ahmad J. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy. Artif Cells Nanomed Biotechnol. 2018;46(sup 2):1188–1198. doi:10.1080/21691401.2018.1481863
   PubMedGoogle Scholar
• Akhter MH, Rizwanullah M, Ahmad J, Ahsan MJ, Mujtaba MA, Amin S. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol. 2018;46(5):873–884. doi:10.1080/21691401.2017.1366333
   PubMed Web of Science ®Google Scholar
• Akhter MH, Amin S. An investigative approach to treatment modalities for squamous cell carcinoma of skin. Curr Drug Deliv. 2017;14(5):597–612. doi:10.2174/1567201801666160906104254
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen H, Chen J, et al. Emodin sensitizes human pancreatic cancer cells to egfr inhibitor through suppressing stat3 signaling pathway. Cancer Manag Res. 2019;11:8463–8473. doi:10.2147/CMAR.S221877
   PubMed Web of Science ®Google Scholar
• Liu DL, Bu H, Li H, et al. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro. Int J Oncol. 2012;40(4):1049–1057. doi:10.3892/ijo.2011.1285
   PubMedGoogle Scholar
• Dai G, Ding K, Cao Q, et al. Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2. Eur J Pharmacol. 2019;859:172525. doi:10.1016/j.ejphar.2019.172525
   PubMed Web of Science ®Google Scholar
• Ma W, Liu F, Yuan L, Zhao C, Chen C. Emodin and AZT synergistically inhibit the proliferation and induce the apoptosis of leukemia K562 cells through the EGR1 and the Wnt/β-catenin pathway. Oncol Rep. 2020;43(1):260–269. doi:10.3892/or.2019.7408
   PubMedGoogle Scholar
• Song M, Zhang Y, Hu S, et al. Influence of morphology and surface exchange reaction on magnetic properties of monodisperse magnetite nanoparticles. Colloids Surfaces A Physicochem Eng Asp. 2012;408:114–121. doi:10.1016/j.colsurfa.2012.05.039
   Google Scholar
• Mero A, Campisi M. Hyaluronic acid bioconjugates for the delivery of bioactive molecules. Polymers. 2014;6(1):346–369. doi:10.1021/bm400612h
   Google Scholar
• Qiu W, Zhang H, Chen X, et al. A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy. Nanomedicine. 2019;14(17):2339–2353. doi:10.2217/nnm-2019-0063
   PubMedGoogle Scholar
• Jin L, Wang Q, Chen J, Wang Z, Xin H, Zhang D. Efficient delivery of therapeutic siRNA by Fe3O4 magnetic nanoparticles into oral cancer cells. Pharmaceutics. 2019;11(11):615. doi:10.3390/pharmaceutics11110615
   PubMed Web of Science ®Google Scholar
• Syed Abdul Rahman SN, Abdul Wahab N, Abd Malek SN. In vitro morphological assessment of apoptosis induced by antiproliferative constituents from the rhizomes of curcuma zedoaria. Evid Based Complement Alternat Med. 2013;2013:257108. doi:10.1155/2013/257108
   PubMedGoogle Scholar
• Guo L, Chen B, Liu R, et al. Biocompatibility assessment of polyethylene glycol-poly L-lysine-poly lactic-co-glycolic acid nanoparticles in vitro and in vivo. J Nanosci Nanotechnol. 2015;15(5):3710–3719. doi:10.1166/jnn.2015.9509
   PubMedGoogle Scholar
• Seyfert UT, Biehl V, Schenk J. In vitro hemocompatibility testing of biomaterials according to the ISO 10993-4. Biomol Eng. 2002;19(2–6):91–96. doi:10.1016/s1389-0344(02)00015-1
   PubMedGoogle Scholar
• Lwin TM, Murakami T, Miyake K, et al. Tumor-specific labeling of pancreatic cancer using a humanized anti-CEA antibody conjugated to a near-infrared fluorophore. Ann Surg Oncol. 2018;25(4):1079–1085. doi:10.1245/s10434-018-6344-6
   PubMedGoogle Scholar
• Hinton JP, Dvorak K, Roberts E, et al. A method to reuse archived H&E stained histology slides for a multiplex protein biomarker analysis. Methods Protoc. 2019;2(4):86. doi:10.3390/mps2040086
   PubMedGoogle Scholar
• Liu B, Wang W, Fan J, et al. RBC membrane camouflaged Prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer. Biomaterials. 2019;217:119301. doi:10.1016/j.biomaterials.2019.119301
   PubMed Web of Science ®Google Scholar
• Jing L, Liang X, Deng Z, et al. Prussian blue coated gold nanoparticles for simultaneous photoacoustic/CT bimodal imaging and photothermal ablation of cancer. Biomaterials. 2014;35(22):5814–5821. doi:10.1016/j.biomaterials.2014.04.005
   PubMed Web of Science ®Google Scholar
• Spill F, Reynolds DS, Kamm RD, Zaman MH. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 2016;40:41–48. doi:10.1016/j.copbio.2016.02.007
   PubMed Web of Science ®Google Scholar
• Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res. 2006;4(2):61–70. doi:10.1158/1541-7786.MCR-06-0002
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17–18):812–818. doi:10.1016/j.drudis.2006.07.005
   PubMed Web of Science ®Google Scholar
• Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release. 2012;164(2):138–144. doi:10.1016/j.jconrel.2012.04.038
   PubMed Web of Science ®Google Scholar
• Akhter MH, Rizwanullah M, Ahmad J, et al. Molecular targets and nanoparticulate systems designed for the improved therapeutic intervention in Glioblastoma Multiforme. Drug Res. 2021;71(3):122–137. doi:10.1055/a-1296-7870
   Web of Science ®Google Scholar
• Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(4):421–437. doi:10.1002/wnan.143
   PubMed Web of Science ®Google Scholar
• Tang Y, Soroush F, Sheffield JB, Wang B, Prabhakarpandian B, Kiani MF. A biomimetic microfluidic tumor microenvironment platform mimicking the EPR effect for rapid screening of drug delivery systems. Sci Rep. 2017;7(1):9359. doi:10.1038/s41598-017-09815-9
   PubMedGoogle Scholar
• Clemons TD, Singh R, Sorolla A, Chaudhari N, Hubbard A, Iyer KS. Distinction between active and passive targeting of nanoparticles dictate their overall therapeutic efficacy. Langmuir. 2018;34(50):15343–15349. doi:10.1021/acs.langmuir.8b02946
   PubMed Web of Science ®Google Scholar
• Pandit S, Dutta D, Nie S. Active transcytosis and new opportunities for cancer nanomedicine. Nat Mater. 2020;19(5):478–480. doi:10.1038/s41563-020-0672-1
   PubMed Web of Science ®Google Scholar
• Chao Y, Karmali PP, Mukthavaram R, et al. Direct recognition of superparamagnetic nanocrystals by macrophage Scavenger Receptor SR-AI. ACS Nano. 2013;7(5):4289–4298. doi:10.1021/nn400769e
   PubMed Web of Science ®Google Scholar
• Pelegri-O’Day EM, Lin EW, Maynard HD. Therapeutic protein-polymer conjugates: advancing beyond PEGylation. J Am Chem Soc. 2014;136(41):14323–14332. doi:10.1021/ja504390x
   PubMed Web of Science ®Google Scholar
• Xu C, Wang Y, Zhang C, Jia Y, Luo Y, Gao X. AuGd integrated nanoprobes for optical/MRI/CT triple-modal in vivo tumor imaging. Nanoscale. 2017;9(13):4620–4628. doi:10.1039/c7nr01064h
   PubMedGoogle Scholar
• Li Y, Guo W, Su X, et al. Facile preparation of near-infrared fluorescence and magnetic resonance dual-modality imaging probes based on mesoporous organosilica nanoparticles. J Colloid Interface Sci. 2019;539:277–286. doi:10.1016/j.jcis.2018.12.067
   PubMedGoogle Scholar
• Kyeong S, Kim J, Chang H, et al. Magnetic nanoparticles. Adv Exp Med Biol. 2021;1309:191–215. doi:10.1007/978-981-33-6158-4_8
   PubMedGoogle Scholar
• Xu Z, Huang H, Xiong X, et al. A near-infrared light-responsive extracellular vesicle as a “Trojan horse” for tumor deep penetration and imaging-guided therapy. Biomaterials. 2021;269:120647. doi:10.1016/j.biomaterials.2020.120647
   PubMed Web of Science ®Google Scholar